senaparib

Senaparib is an orally bioavailable, small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, developed by IMPACT Therapeutics. It acts by selectively binding to PARP1 and PARP2, thereby inhibiting PARP-mediated DNA repair of single-strand breaks via the base-excision repair pathway. This inhibition leads to accumulation of DNA damage in cancer cells, promoting genomic instability and apoptosis through synthetic lethality. Senaparib has demonstrated high potency, selectivity for its targets, a wide safety window in preclinical studies, and significant clinical benefit as maintenance therapy for advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer following response to first-line platinum-based chemotherapy. It was approved in China in January 2025 for this indication based on results from the pivotal Phase III FLAMES trial[1][3][4][5][6].

Brand names

派舒宁

Other names

senaparib [INN]1401682-78-7